CABA Cabaletta Bio Inc

Price (delayed)

$3.54

Market cap

$577.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.91

Enterprise value

$487.03M

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 2

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, ...

Highlights
CABA's EPS is up by 25% YoY and by 9% QoQ
CABA's debt is down by 8% year-on-year and by 2.4% since the previous quarter
Cabaletta Bio's quick ratio has decreased by 28% YoY but it has increased by 6% QoQ
CABA's net income is down by 38% year-on-year and by 4.5% since the previous quarter
The equity has contracted by 15% YoY and by 8% from the previous quarter

Key stats

What are the main financial stats of CABA

CABA stock price

How has the Cabaletta Bio stock price performed over time
Intraday
-1.12%
1 week
-6.1%
1 month
-7.57%
1 year
60.18%
YTD
61.64%
QTD
31.6%

Financial performance

How have Cabaletta Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$179.4M
Net income
-$175.43M
Gross margin
N/A
Net margin
N/A
CABA's net income is down by 38% year-on-year and by 4.5% since the previous quarter
The operating income has contracted by 34% YoY and by 4.2% from the previous quarter

Price vs fundamentals

How does CABA's price correlate with its fundamentals

Growth

What is Cabaletta Bio's growth rate over time

Valuation

What is Cabaletta Bio stock price valuation
P/E
N/A
P/B
3.81
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CABA's EPS is up by 25% YoY and by 9% QoQ
CABA's price to book (P/B) is 127% higher than its last 4 quarters average of 1.7 and 103% higher than its 5-year quarterly average of 1.9
The equity has contracted by 15% YoY and by 8% from the previous quarter

Efficiency

How efficient is Cabaletta Bio business performance
Cabaletta Bio's ROE has plunged by 68% YoY and by 8% from the previous quarter
The ROIC has grown by 49% YoY but it has contracted by 9% from the previous quarter
Cabaletta Bio's return on assets has decreased by 47% YoY and by 7% QoQ

Dividends

What is CABA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CABA.

Financial health

How did Cabaletta Bio financials performed over time
Cabaletta Bio's quick ratio has decreased by 28% YoY but it has increased by 6% QoQ
The current ratio has contracted by 26% YoY but it has grown by 6% from the previous quarter
CABA's debt is 74% smaller than its equity
The equity has contracted by 15% YoY and by 8% from the previous quarter
Cabaletta Bio's debt to equity has increased by 8% from the previous quarter and by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.